热门资讯> 正文
雅培将与Cadrenal合作开发抗凝血剂替卡必拓
2024-08-06 22:50
- Abbott Laboratories (NYSE:ABT) has agreed to collaborate with Cadrenal Therapeutics (NASDAQ:CVKD) on the latter's pivotal study for its anticoagulant candidate tecarfarin.
- The oral blood thinner is aimed at patients with implanted cardiac devices and those with rare cardiovascular conditions.
- The trial will investigate tecarfarin in patients with recently implanted left ventricular assist devices. Abbott makes the only LVAD available in the U.S., the HeartMate 3.
- Tecfarin also has Orphan Drug status from the U.S. FDA.
More on Abbott, Cadrenal Therapeutics
- Abbott Laboratories: A Strong Healthcare Stock For Long-Term Dividend Growth Investors
- Abbott Laboratories (ABT) Q2 2024 Earnings Call Transcript
- Abbott Laboratories: When Double-Digit Device Growth Apparently Isn't Enough
- DexCom, Abbott to benefit from the multi-billion-dollar OTC continuous glucose market
- Abbott likely to settle baby formula cases for $200M-$300M - analyst
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
